Cargando…
Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
BACKGROUND: Precision oncology uses molecular profiling of tumors to identify biomarker‐tailored therapies for patients in the hope of improving outcomes. Typically, only a minority of patients receives evaluable matched treatment. This study explored the reasons for attrition on a precision medicin...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648352/ https://www.ncbi.nlm.nih.gov/pubmed/32949172 http://dx.doi.org/10.1002/onco.13532 |
_version_ | 1783607095550017536 |
---|---|
author | Bohan, Sandy S. Sicklick, Jason K. Kato, Shumei Okamura, Ryosuke Miller, Vincent A. Leyland‐Jones, Brian Lippman, Scott M. Kurzrock, Razelle |
author_facet | Bohan, Sandy S. Sicklick, Jason K. Kato, Shumei Okamura, Ryosuke Miller, Vincent A. Leyland‐Jones, Brian Lippman, Scott M. Kurzrock, Razelle |
author_sort | Bohan, Sandy S. |
collection | PubMed |
description | BACKGROUND: Precision oncology uses molecular profiling of tumors to identify biomarker‐tailored therapies for patients in the hope of improving outcomes. Typically, only a minority of patients receives evaluable matched treatment. This study explored the reasons for attrition on a precision medicine trial. MATERIALS AND METHODS: Study participants were 190 adult patients who consented to the I‐PREDICT (Investigation of molecular Profile‐Related Evidence Determining Individualized Cancer Therapy) trial. Patients had metastatic and/or unresectable incurable malignancies. Patients who were not evaluable were analyzed. RESULTS: Of consented patients, 44% were not evaluable. Men were twice as likely to be not evaluable as women. Prominently, 45% of patients who were not evaluable dropped off because of death, hospice referral, or decline in organ function. CONCLUSION: Health deterioration of consented patients is a significant barrier to being evaluable on the I‐PREDICT trial. These data suggest that patients are enrolled on precision oncology trials too late in their disease course or with excessive disease burden. |
format | Online Article Text |
id | pubmed-7648352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76483522020-11-16 Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience Bohan, Sandy S. Sicklick, Jason K. Kato, Shumei Okamura, Ryosuke Miller, Vincent A. Leyland‐Jones, Brian Lippman, Scott M. Kurzrock, Razelle Oncologist Brief Communications BACKGROUND: Precision oncology uses molecular profiling of tumors to identify biomarker‐tailored therapies for patients in the hope of improving outcomes. Typically, only a minority of patients receives evaluable matched treatment. This study explored the reasons for attrition on a precision medicine trial. MATERIALS AND METHODS: Study participants were 190 adult patients who consented to the I‐PREDICT (Investigation of molecular Profile‐Related Evidence Determining Individualized Cancer Therapy) trial. Patients had metastatic and/or unresectable incurable malignancies. Patients who were not evaluable were analyzed. RESULTS: Of consented patients, 44% were not evaluable. Men were twice as likely to be not evaluable as women. Prominently, 45% of patients who were not evaluable dropped off because of death, hospice referral, or decline in organ function. CONCLUSION: Health deterioration of consented patients is a significant barrier to being evaluable on the I‐PREDICT trial. These data suggest that patients are enrolled on precision oncology trials too late in their disease course or with excessive disease burden. John Wiley & Sons, Inc. 2020-10-02 2020-11 /pmc/articles/PMC7648352/ /pubmed/32949172 http://dx.doi.org/10.1002/onco.13532 Text en © 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Brief Communications Bohan, Sandy S. Sicklick, Jason K. Kato, Shumei Okamura, Ryosuke Miller, Vincent A. Leyland‐Jones, Brian Lippman, Scott M. Kurzrock, Razelle Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience |
title | Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience |
title_full | Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience |
title_fullStr | Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience |
title_full_unstemmed | Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience |
title_short | Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience |
title_sort | attrition of patients on a precision oncology trial: analysis of the i‐predict experience |
topic | Brief Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648352/ https://www.ncbi.nlm.nih.gov/pubmed/32949172 http://dx.doi.org/10.1002/onco.13532 |
work_keys_str_mv | AT bohansandys attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience AT sicklickjasonk attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience AT katoshumei attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience AT okamuraryosuke attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience AT millervincenta attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience AT leylandjonesbrian attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience AT lippmanscottm attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience AT kurzrockrazelle attritionofpatientsonaprecisiononcologytrialanalysisoftheipredictexperience |